These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34351500)

  • 21. Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy.
    Takashi Y; Kinoshita Y; Hori M; Ito N; Taguchi M; Fukumoto S
    Endocr Res; 2017 May; 42(2):132-137. PubMed ID: 27754732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Bone and bone related biochemical examinations. Hormone and hormone related substances. The measurement of circulating fibroblast growth factor 23 (FGF-23)].
    Kobayashi K; Imanishi Y
    Clin Calcium; 2006 Jun; 16(6):935-39. PubMed ID: 16751688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
    Fukumoto S
    Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
    Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
    Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FGF23-related hypophosphatemia in patients with low bone mineral density and fragility fractures: challenges in diagnosis and management.
    Indirli R; Guabello G; Longhi M; Niada S; Maruca K; Mora S; Maggioni M; Corbetta S
    J Endocrinol Invest; 2020 Jun; 43(6):787-798. PubMed ID: 31863362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Fibroblast growth factor (FGF) 23 works as a phosphate-regulating hormone and is involved in the pathogenesis of several disorders of phosphate metabolism].
    Fukumoto S
    Rinsho Byori; 2007 Jun; 55(6):555-9. PubMed ID: 17657990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bone and Calcium Research Update 2015. Novel treatment for FGF23-related hypophosphatemic diseases].
    Fukumoto S
    Clin Calcium; 2015 Jan; 25(1):37-44. PubMed ID: 25530521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.
    Goldsweig BK; Carpenter TO
    Curr Osteoporos Rep; 2015 Apr; 13(2):88-97. PubMed ID: 25620749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Significance of FGF23 measurement].
    Fukumoto S
    Clin Calcium; 2012 Oct; 22(10):1525-9. PubMed ID: 23023632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGF23 and Bone and Mineral Metabolism.
    Fukumoto S
    Handb Exp Pharmacol; 2020; 262():281-308. PubMed ID: 31792685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rickets/Osteomalacia. FGF23-related hypophosphatemic rickets/osteomalacia.].
    Fukumoto S
    Clin Calcium; 2018; 28(10):1313-1317. PubMed ID: 30269112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
    Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
    Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anti-FGF23 antibody therapy for patients with tumor-induced osteomalacia].
    Kinoshita Y; Fukumoto S
    Clin Calcium; 2014 Aug; 24(8):1217-22. PubMed ID: 25065874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak.
    Rendina D; Mossetti G; De Filippo G; Cioffi M; Strazzullo P
    J Clin Endocrinol Metab; 2006 Mar; 91(3):959-63. PubMed ID: 16352682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia].
    Michigami T
    Clin Calcium; 2013 Oct; 23(10):1429-35. PubMed ID: 24076640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Epidemiology of FGF23-related hypophosophatemic diseases].
    Endo I
    Clin Calcium; 2016 Feb; 26(2):223-31. PubMed ID: 26813502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenic role of Fgf23 in Dmp1-null mice.
    Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a novel loss-of-function PHEX mutation, Ala720Ser, in a sporadic case of adult-onset hypophosphatemic osteomalacia.
    Goljanek-Whysall K; Tridimas A; McCormick R; Russell NJ; Sloman M; Sorani A; Fraser WD; Hannan FM
    Bone; 2018 Jan; 106():30-34. PubMed ID: 28982589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical usefulness of the determination of fibroblast growth factor 23 in the evaluation of patients with osteomalacia].
    Gifre L; Martínez de Osaba MJ; Monegal A; Guañabens N; Peris P
    Med Clin (Barc); 2014 May; 142(10):447-50. PubMed ID: 24629692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-fibroblast growth factor 23 antibody therapy.
    Fukumoto S
    Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):346-51. PubMed ID: 24848934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.